Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation: A matched case-control study

Oncology

Volumn 72, Issue SUPPL. 1, 2007, Pages 132-138

  Kudo, Masatoshi ^a   Sakaguchi, Yasuhiro ^a   Chung, Hobyung ^a   Hatanaka, Kinuyo ^a   Hagiwara, Satoru ^a   Ishikawa, Emi ^a   Takahashi, Shunsuke ^a   Kitai, Satoshi ^a   Inoue, Tatsuo ^a   Minami, Yasunori ^a   Ueshima, Kazuomi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Interferon maintenance therapy; Radiofrequency ablation therapy

Indexed keywords

ALPHA2B INTERFERON; NEOMINOPHAGEN C; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; URSODEOXYCHOLIC ACID;

ADULT; AGED; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASE CONTROL STUDY; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FLU LIKE SYNDROME; HEPATITIS C VIRUS; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER CELL CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIOFREQUENCY ABLATION; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CATHETER ABLATION; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 37149036135     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111719     Document Type: Conference Paper

References (27)

1. El-Serag HB: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107.
2. El-Serag HB: Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35:S72-S78.
3. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-1380.
4. Bosch FX, Ribes J, Cleries R, Diaz M: Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211.
5. Kiyosawa K, Umemura T, Ichijyo T, Matsumoto A, Yoshizawa K, Gad A, et al: Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17-S26.
6. National Institutes of Health: National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology 2002;36(suppl 1):S3-S20.
7. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S: Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
8. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Takafuchi Y, Kojiro M: Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004;41:782-789.
9. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T: Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005;48:64-70.
10. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, et al: Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301-311.
11. Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al: Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation. Hepatogastroenterology 1999;46:3212-3215.
12. Benvegnu L, Alberti A: Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 2001;52:199-207.
13. Kudo M: Local ablation therapy for hepatocellular carcinoma: current status and future perspective. J Gastroenterol 2004;39:205-214.
14. Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, et al: Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16:1131-1137.
15. Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al: Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 2003;23:593-596.
16. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306.
17. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963-967.
18. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422.
19. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamto T, Shuto T, et al: Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 2001;92:59-66.
20. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232.
21. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, et al: Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004;41:782-789.
22. Von Marschall Z, Scholz A, Cramer T, Scafer G, Schirner M, Oberg K, et al: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448.
23. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, Liu YK, et al: Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 2003;7:587-594.
24. Murphy D, Detjen KM, Welzel M, Wiedenmann B, Rosewicz S: Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001;33:346-356.
25. Yano H, Iemura A, Haramaki, Ogasawara S, Takayama A, Akiba J, et al: Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cancer cell lines. Hepatology 1999;29:1708-1717.
26. Mallat DB, El-Serag HB: Interferon for postresection recurrence of hepatocellular carcinoma. Am J Gastroenterol 2002;97:3200-3202.
27. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382.